What is AmideBio?
AmideBio operates at the intersection of computational biology and pharmaceutical manufacturing. The company specializes in the development of novel peptide drug candidates, utilizing a sophisticated in-silico design platform to address complex metabolic disorders. Beyond its internal drug discovery pipeline, AmideBio maintains a robust commercial arm, providing custom synthesis services and a catalog of high-purity peptides to a global client base of pharmaceutical and biotechnology enterprises. This dual-revenue model allows the company to sustain its research-heavy operations while providing immediate value to the broader life sciences ecosystem through cost-effective, high-quality chemical solutions.
How much funding has AmideBio raised?
AmideBio has raised a total of $3.5M across 2 funding rounds:
Private Equity
$763K
Grant
$2.7M
Private Equity (2017): $763K, investors not publicly disclosed
Grant (2022): $2.7M led by The National Institute of Diabetes and Digestive and Kidney Diseases
Key Investors in AmideBio
The National Institute of Diabetes and Digestive and Kidney Diseases
The National Institute of Diabetes and Digestive and Kidney Diseases is a federal agency under the NIH that funds critical research into chronic diseases, providing essential non-dilutive capital for high-impact medical innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AmideBio?
With the recent infusion of capital, AmideBio is poised to accelerate its clinical development programs and expand its proprietary peptide synthesis capabilities. The strategic focus will likely shift toward scaling its in-silico design platform to address a broader spectrum of metabolic therapeutic targets. As the company matures, the integration of its custom synthesis services with its internal drug discovery efforts will be essential for maintaining a competitive edge in the pharmaceutical market. Future growth will depend on the successful translation of its peptide candidates into clinical trials, further validating its unique approach to metabolic disease management and solidifying its standing as a leader in peptide-based therapeutics.
See full AmideBio company page
